Novogenia AG

7V0 · XETRA · Healthcare / Biotechnology

6.25EUR-0.20 (-3.10%)

Price History

Full chart

Market Stats

Previous Close6.45

Open6.40

Day Range6.20 – 6.45

52-Week Range5.55 – 11.01

Volume820

Market Cap76.80M

P/E (TTM)128.00

Forward P/E103.09

EPS0.05

Dividend Yield8.12%

Beta0.30

50-Day Avg6.56

200-Day Avg7.74

About

Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Daniel Wallerstorfer B.Sc., Ph.D.
Employees204
HeadquartersBrienner Strasse 7, Munich, Germany, 80333, Germany
Websitehttps://www.novogenia.com

Leadership

Dr. Daniel Wallerstorfer B.Sc., Ph.D.Founder, CEO & Member of Management Board
Ms. Felix BauschMember of Management Board & C.I.O

Financials

Income Statement

Currency: EUR	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	111.32M	210.34M	18.17M	25.29M	54.30M
Growth (%)	-	+88.95%	-91.36%	+39.21%	+114.69%
Cost of Revenue	55.74M	90.51M	12.14M	12.90M	35.93M
Gross Profit	55.58M	119.84M	6.03M	12.39M	18.38M
Gross Margin	49.93%	56.97%	33.21%	49.00%	33.84%
Operating Expense	25.92M	54.78M	9.78M	-13.98M	29.15M
Operating Income	29.66M	65.05M	-3.74M	26.37M	-10.78M
Operating Margin	26.64%	30.93%	-20.60%	104.25%	-19.85%
EBITDA	-	67.52M	8.65M	36.82M	6.49M
EBITDA Margin	-	32.10%	47.63%	145.57%	11.95%
Net Income	19.39M	45.07M	39.71K	18.46M	545.47K
Net Income Margin	17.42%	21.43%	0.22%	72.98%	1.00%
Interest Expense	49.37K	28.42K	282.92K	363.37K	547.87K
Interest Expense % of Total Revenue	0.04%	0.01%	1.56%	1.44%	1.01%

Balance Sheet

Currency: EUR	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	161.76M	223.81M	178.90M	152.96M	119.38M
Total Liabilities	92.73M	109.67M	85.13M	46.77M	19.29M
Total Equity	68.73M	112.02M	93.88M	105.83M	100.16M
Cash	39.94M	90.12M	18.45M	20.66M	12.53M

Cash Flow

Currency: EUR	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	10.38M	95.15M	-18.95M	-24.89M	-12.97M
Capital Expenditure	891.21K	2.61M	1.45M	4.34M	8.67M
Free Cash Flow	9.49M	92.54M	-20.39M	-29.23M	-21.65M
Dividends Paid	2.20M	1.56M	2.54M	2.06M	3.58M
FCF to OCF	91.41%	97.26%	107.63%	117.45%	166.87%
Dividend Paid to FCF	23.19%	1.69%	-12.44%	-7.04%	-16.54%

Earnings

Report Date	Sep 30, 2025	Dec 31, 2025
EPS Estimate	-	-
EPS Actual	0.16	-0.24
Surprise	-	-
Timing	-	-

Key Statistics & Ratios

Market Cap76.80M

Enterprise Value34.74M

Trailing P/E128.00

Forward P/E103.09

Price / Sales1.47

Price / Book0.89

EPS0.05

Book Value7.67

Revenue (TTM)52.35M

Gross Profit (TTM)20.20M

EBITDA-11.02M

Profit Margin-6.56%

Operating Margin-18.24%

Return on Equity0.53%

Return on Assets-4.95%

Shares Outstanding12.00M

Shares Float5.10M

Beta0.30

Dividend Yield8.12%

Dividend Rate0.56

Payout Ratio1125.00%

Dividends

20261×

0.56Jun 29, 2026

20251×

0.56Jun 30, 2025

20241×

0.56Jun 19, 2024

Stock Splits

Sep 18, 20254:1